Milk thistle's active compound silymarin is the most studied hepatoprotective (liver-protective) natural compound, with evidence spanning alcoholic liver disease, NAFLD, drug-induced liver injury, and hepatitis. Our research shows it genuinely protects liver cells — but the bioavailability of standard silymarin is very poor. Phytosomal forms (Siliphos, Silybin Phytosome) dramatically improve absorption and clinical outcomes.
Silymarin inhibits CYP3A4 in vitro; clinical significance debated
In vitro inhibition; may increase warfarin levels
Silymarin inhibits glucuronidation; may affect drug clearance
Case report of increased sirolimus levels
Silymarin may enhance metformin's effects on blood sugar
Both metabolized via CYP3A4; potential for increased statin levels
Not Prohibited
Zhong S et al. The therapeutic effect of silymarin in NAFLD: a meta-analysis.
Abenavoli L et al. Milk thistle in liver diseases: past, present, future.
Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome.
Voroneanu L et al. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated: April 2026
Not medical advice. Based on published clinical research and systematic reviews.